| Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy UH Gandhi, RF Cornell, A Lakshman, ZJ Gahvari, E McGehee, ... Leukemia 33 (9), 2266-2275, 2019 | 516 | 2019 |
| Novel therapies emerging in oncology to target the TGF-β pathway BG Kim, E Malek, SH Choi, JJ Ignatz-Hoover, JJ Driscoll Journal of hematology & oncology 14, 1-20, 2021 | 256 | 2021 |
| Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial MV Mateos, H Blacklock, F Schjesvold, A Oriol, D Simpson, A George, ... The Lancet Haematology 6 (9), e459-e469, 2019 | 227 | 2019 |
| Correlation of long non-coding RNA expression with metastasis, drug resistance and clinical outcome in cancer E Malek, S Jagannathan, JJ Driscoll Oncotarget 5 (18), 8027, 2014 | 216 | 2014 |
| NCCN guidelines insights: multiple myeloma, version 3.2018 SK Kumar, NS Callander, M Alsina, D Atanackovic, JS Biermann, ... Journal of the National Comprehensive Cancer Network 16 (1), 11-20, 2018 | 154 | 2018 |
| NCCN guidelines insights: Multiple myeloma, version 1.2020: Featured updates to the NCCN guidelines SK Kumar, NS Callander, J Hillengass, M Liedtke, M Baljevic, ... Journal of the National Comprehensive Cancer Network 17 (10), 1154-1165, 2019 | 152 | 2019 |
| Myeloid-derived suppressor cells: The green light for myeloma immune escape E Malek, M de Lima, JJ Letterio, BG Kim, JH Finke, JJ Driscoll, SA Giralt Blood reviews 30 (5), 341-348, 2016 | 143 | 2016 |
| Pharmacologic screens reveal metformin that suppresses GRP78-dependent autophagy to enhance the anti-myeloma effect of bortezomib S Jagannathan, MAY Abdel-Malek, E Malek, N Vad, T Latif, KC Anderson, ... Leukemia 29 (11), 2184-2191, 2015 | 116 | 2015 |
| Molecular chaperone GRP78 enhances aggresome delivery to autophagosomes to promote drug resistance in multiple myeloma MAYA Malek, S Jagannathan, E Malek, DM Sayed, SA Elgammal, ... Oncotarget 6 (5), 3098, 2015 | 85 | 2015 |
| Deciphering mechanisms of immune escape to inform immunotherapeutic strategies in multiple myeloma M Swamydas, EV Murphy, JJ Ignatz-Hoover, E Malek, JJ Driscoll Journal of Hematology & Oncology 15 (1), 17, 2022 | 61 | 2022 |
| Age no bar: a CIBMTR analysis of elderly patients undergoing autologous hematopoietic cell transplantation for multiple myeloma PN Munshi, D Vesole, A Jurczyszyn, JM Zaucha, A St. Martin, O Davila, ... Cancer 126 (23), 5077-5087, 2020 | 56 | 2020 |
| Pharmacogenomics and chemical library screens reveal a novel SCFSKP2 inhibitor that overcomes Bortezomib resistance in multiple myeloma E Malek, MAY Abdel-Malek, S Jagannathan, N Vad, R Karns, AG Jegga, ... Leukemia 31 (3), 645-653, 2017 | 54 | 2017 |
| Significance of the absolute lymphocyte/monocyte ratio as a prognostic immune biomarker in newly diagnosed multiple myeloma T Dosani, F Covut, R Beck, JJ Driscoll, M De Lima, E Malek Blood cancer journal 7 (6), e579-e579, 2017 | 52 | 2017 |
| Pomalidomide plus low‐dose dexamethasone in relapsed refractory multiple myeloma after lenalidomide treatment failure DS Siegel, GJ Schiller, KW Song, R Agajanian, K Stockerl‐Goldstein, ... British journal of haematology 188 (4), 501-510, 2020 | 50 | 2020 |
| MicroRNAs in brain metastases: potential role as diagnostics and therapeutics S Alsidawi, E Malek, JJ Driscoll International Journal of Molecular Sciences 15 (6), 10508-10526, 2014 | 49 | 2014 |
| Gastrointestinal microbiome and mycobiome changes during autologous transplantation for multiple myeloma: results of a prospective pilot study N El Jurdi, A Filali-Mouhim, I Salem, M Retuerto, NM Dambrosio, L Baer, ... Biology of Blood and Marrow Transplantation 25 (8), 1511-1519, 2019 | 42 | 2019 |
| Interference of therapeutic monoclonal antibodies with routine serum protein electrophoresis and immunofixation in patients with myeloma: frequency and duration of detection of … F Tang, E Malek, S Math, CL Schmotzer, RC Beck American Journal of Clinical Pathology 150 (2), 121-129, 2018 | 41 | 2018 |
| Bortezomib induces AMPK-dependent autophagosome formation uncoupled from apoptosis in drug resistant cells S Jaganathan, E Malek, S Vallabhapurapu, S Vallabhapurapu, JJ Driscoll Oncotarget 5 (23), 12358, 2014 | 41 | 2014 |
| Metabolic tumor volume on interim PET is a better predictor of outcome in diffuse large B-cell lymphoma than semiquantitative methods E Malek, A Sendilnathan, M Yellu, A Petersen, M Fernandez-Ulloa, ... Blood Cancer Journal 5 (7), e326-e326, 2015 | 39 | 2015 |
| A phase I/II trial of MEC (mitoxantrone, etoposide, cytarabine) in combination with ixazomib for relapsed refractory acute myeloid leukemia AS Advani, B Cooper, V Visconte, P Elson, R Chan, J Carew, W Wei, ... Clinical Cancer Research 25 (14), 4231-4237, 2019 | 36 | 2019 |
